An update on disease modifying antirheumatic drugs

Inflammation and Allergy - Drug Targets

Volumn 13, Issue 4, 2014, Pages 249-261

  Joshi, Poorvashree ^a   Dhaneshwar, Suneela S ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Arthritis; Biological DMARDs; Disease modifying antirheumatic drugs; IL 1; Non biologic DMARDs; TNF

Indexed keywords

ABATACEPT; ADALIMUMAB; AUROTHIOGLUCOSE; AZATHIOPRINE; CATHEPSIN; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENTERACEPT; GLYCOSIDASE INHIBITOR; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; PENICILLAMINE; SALAZOSULFAPYRIDINE; TOCLIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ANEMIA; ANGIOGENESIS; APOPTOSIS; ARTHRITIS; ARTICLE; CROHN DISEASE; CYTOPENIA; DIARRHEA; DISEASE COURSE; DRUG BIOAVAILABILITY; HEADACHE; HUMAN; HYPERTENSION; INFLAMMATION; INTERVENTION STUDY; KIDNEY DISEASE; KIDNEY FAILURE; LOSS OF APPETITE; LUPUS LIKE SYNDROME; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PROTEINURIA; RASH; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; VOMITING; ARTHRITIS, RHEUMATOID; METABOLISM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; INFLAMMATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923019971     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152811304140915152102     Document Type: Article

References (88)

1. http://www.webmd.com/rheumatoid-arthritis/guide/dmardrheumatoid-arthritis-treatment (accessed on Aug 17, 2013).
2. http://www.webmd.com/rheumatoid-arthritis/guide/dmardrheumatoid-arthritis-treatment (accessed on Aug 20, 2013).
3. Ferdinand, B. Current and future management approaches for rheumatoid arthritis. Arthritis Res., 2002, 4(2), S16-S21.
4. Sulaiman, W.; Toib, A.; Chandrashekhar, G.; Arshad, A. The trends of DMARDS prescribed in rheumatoid arthritis patients in Malaysia. Oman. Med. J., 2009, 24(4), 260-266.
5. Kremer, J.M.; Bloom, B.J.; Breedveld, F.C. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum., 2009, 60, 1895-1905.
6. Roy, F. Don’t forget traditional DMARDs. Rheumatology, 2011, 50(3), 429-430.
7. Kelley, W.N.; Rosenbloom, F.M.; Seegmiller, J. E. The Effects of Azathioprine (Imuran) on Purine Synthesis in Clinical Disorders of Purine Metabolism. J. Clin. Invest., 1967, 46(9), 1518-1529.
8. Alldred, A.; Emery, P. Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis. Expert Opin. Pharmacother., 2001, 2(1), 125-137.
9. Joost, W. A.; Ben, A. D.; Rik, J. S.; Gerrit, J. Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside. Nat. Clin. Pract. Rheumatol., 2007, 3(1), 26-34.
10. Kitahara, K.; Kawai, S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis, Curr. Opin. Rheumatol., 2007, 19(3), 238-245.
11. Ling-dong, Q.; Geoffrey, T.; Jun, T.; Dong, W. The Development of novel therapies for rheumatoid arthritis. Expert Opin. Ther. Pat., 2008, 18(7), 723-738.
12. Vanhaesebroeck, B.; Guillermet-Guibert, J.; Graupera, M.; Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol., 2010, 11(5), 329-341.
13. Rommel, C.; Camps, M.; Ji, H. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev., 2007, 7(3), 191-201.
14. Wymann, M. P.; Bulgarelli-Leva, G.; Zvelebil, M. J.; Pirola, L.; Vanhaesebroeck, B.; Waterfield, M.D. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell Biol., 1996, 16(4), 1722-1733.
15. Boyle, D. L.; Kim, H. R.; Topolewski, K.; Beatrix, B.; Gary, S. F. Novel dual phosphoinositide 3-kinase-δ, γ inhibitor: Potent antiinflammatory effects and joint protection in models of rheumatoid arthritis. J. Pharmacol. Exp. Ther., 2014, 348(2), 271-280.
16. Woessner, J. F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J., 1991, 5, 2145-2154.
17. Martel-Pelletier, J.; Fujimoto, N.; Obata, K.; Cloutier, J. M.; Pelletier, J. P. The imbalance between the synthesis level of metalloproteinases and TIMPs in osteoarthritic and rheumatoid arthritis cartilage can be enhanced by interleukin-1. Arthritis Rheum., 1993, 36(9), S191-S192.
18. Posthumus, M.D.; Limburg, P.C.; Westra, J.; van Leeuwen, M. A.; van Rijswijk, M. H. Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression. J. Rheumatol., 2000, 27, 2761-2768.
19. Close, D. R. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann. Rheum. Dis., 2001, 60(3), 62-67.
20. Jackson, C.; Nguyen, M.; Arkell.; Sambrook, P. Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis--targetting gelatinase A activation. Inflamm. Res., 2001, 50(4), 183-186.
21. Rasmussen, H. S.; McCann, P. P. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol. Ther., 1997, 75, 69-75.
22. Dasgupta S.; Murumkar P. R.; Giridhar R.; Yadav M. R. Current perspective of TACE inhibitors: a review. Bioorg. Med. Chem., 2009, 17(2), 444-459.
23. Weidauer, E.; Yasuda, Y.; Biswal, B. K.; Cherny, M.; James, M. N.; Bromme, D. Effects of disease-modifying anti-rheumatic drugs (DMARDs) on the activities of rheumatoid arthritis-associated cathepsins K and S. Biol. Chem., 2007, 388(3), 331-336.
24. Ikeda, Y.; Ikata, T.; Mishiro, T.; Nakano, S.; Ikebe, M.; Yasuoka, S. Cathepsins B and L in synovial fluids from patients with rheumatoid arthritis and the effect of cathepsin B on the activation of pro-urokinase. J. Med. Invest., 2000, 47(1-2), 61-75.
25. Popko, J.; Mnich, Z.; Kilczewska, D.; Trembaczowski, E. Topographical differences in the content and composition of glycosaminoglycans of patellar cartilage. Reumatologia, 1983, 21, 129-133.
26. Bruce, A.B. Synovial fluid glycosidase activity. Scand J. Rheumatol., 1972, 1(2), 69-74.
27. Zsuzsanna, O.; Anna, P.; Bela, G.; Pal, G.; Tamas, L. Synovial fluid exoglycosidases are predictors of rheumatoid arthritis and are effective in cartilage glycosaminoglycan depletion. Arthritis Rheum., 2003, 48(8), 2163-2172.
28. Cutolo, M.; Sulli, A.; Pizzorni, C.; Seriolo, B. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann. Rheum. Dis., 2001, 60, 729-735.
29. Montesinos, M.; Desai, A.; Delano, D. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum., 2003, 48(1), 240-247.
30. Henghe, T.; Bruce, N. C. Understanding the mechanisms of action of methotrexate implications for the treatment of rheumatoid arthritis. Bull. NYU Hosp. Joint Dis., 2007, 65(3), 168-173.
31. Chan, E. S.; Cronstein B. N. Molecular action of Methotrexate in inflammatory disease. Arthritis Res., 2001, 4(4), 266-273.
32. Lee, S.; Kavanaugh, A. Pharmacological treatment of established rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol., 2003, 17(5), 811-829.
33. http://www.rheumatology.org/Practice/Clinical/Patients/Medications/Sulfasalazine_(Azulfidine) (accessed on Nov 23, 2013).
34. Rains, C.; Noble, S.; Faulds, D. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs, 1995, 50(1), 137-156.
35. http://www.drugs.com/monograph/sulfasalazine.html (accessed on Nov 26, 2013).
36. http://www.medsafe.govt.nz/profs/datasheet/s/SalazopyrintabENtab.pdf (accessed on Dec 10, 2013).
37. http://www.medsafe.govt.nz/profs/datasheet/s/SalazopyrintabENtab.pdf (accessed on Dec 15, 2013).
38. http://www.drugs.com/monograph/sulfasalazine.html (accessed on Dec 20, 2013).
39. Hochberg, M. C. Rheumatology, 5th ed.; Elsevier: Mosby, 2010, pp. 2384.
40. Lemke, T. M.; Williams, D. A. Foye’s Principles of Medicinal Chemistry; Lippincott Williams & Wilkins, 2012, pp. 1027.
41. Kale, V.; Bichile, L. Leflunomide: A novel disease modifying antirheumatic drug. J. Postgrad. Med., 2004, 50(2), 154-157.
42. Chien-Ming, H.; Yong-Hong, H.; Wen-Hsin, H.; An-Rong L. Anti-inflammatory Activity and Structure-activity relationships of 2-hydroxy-N-(alkylphenyl)nicotinamides. Taiwan Pharmaceut. J., 2007, 59, 105-112.
43. Heusler, K.; Pletscher, A. The controversial early history of cyclosporin. Swiss Med. Wkly, 2001, 131, 299-302.
44. Wong, R. Mechanisms of action of cyclosporin A in animal models of rheumatoid arthritis. Inflammopharmacol, 1993, 2, 177-195.
45. Fahr, A. Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet., 1993, 24(6), 472-495.
46. Ptachcinski, R.; Venkataramanan, R.; Burckart, G. Clinical pharmacokinetics of cyclosporin. Clin. Pharmacokinet., 1986, 11(2), 107-32.
47. Norga, K.; Grillet, B.; Masure, S; Paemen, L.; Opdenakker, G. Human gelatinase B, a marker enzyme in rheumatoid arthritis, is inhibited by D-penicillamine: Anti-rheumatic activity by protease inhibition. Clin. Rheumatol., 1996, 15(1), 31-34.
48. Gowdie, P. Review of Disease_modifying anti rheumatic drugs in paediatric rheumatic disease: Eighteenth expert committee on the selection and use of essential medicines, Royal Children’s Hospital Melbourne, Australia, 21-25 Mar 2011.
49. Qi-Quan, H.; Richard, M. P. Role of toll like receptors in rheumatoid arthritis. Curr. Rheumatol. Rep., 2009, 11(5), 357-364.
50. Fox, R. I. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin. Arthritis Rheum., 1993, 23,82-91.
51. Furst, D. E. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus, 1996, 5(1), S11-15.
52. McLachlan, A.; Tett, S.; Cutler, D.; Day, R. Disposition and absorption of hydroxychloroquine enantiomers following a single dose of the racemate. Chirality, 1994, 6(4), 360-364.
53. Tett, S. E.; Cutler, D.J.; Day, R. O.; Brown, K, F. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br. J. Clin. Pharmacol., 1989, 27(6), 771-779.
54. Carmem, D. C.; Pierina, S. B. Enantioselective metabolism of hydroxychloroquine employing rats and mice hepatic microsomes. Brazilian J. Pharm. Sci., 2009, 45(4), 659-667.
55. Miller, D. R.; Khalil, S. K.; Nygard, G. A. Steady-state pharmacokinetics of hydroxychloroquine in rheumatoid arthritis patients. DICP, 1991, 25(12), 1302-1305.
56. Doan, Q. V.; Chiou, C. F.; Dubois, R. W. Review of eight pharmacoeconomic studies of the value of biologic dmards (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J. Manag. Care Pharm., 2006, 12(7), 555-569.
57. Maini, R. N.; Feldmann, M. How does infliximab work in rheumatoid arthritis?. Arthritis Res., 2002, 4(2), S22-S28.
58. Bansback, N.; Brennan, A. The efficacy of inhibiting tumour necrosis factor α and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatol., 2007, 46(7), 1140-1147.
59. Hirano, T.; Taga, T.; Matsuda, T. Interleukin 6 and its receptor in the immune response and hematopoiesis. Int. J. Cell Cloning, 1990, 8(1), 155-166.
60. Mimura, T. Selection of one of the TNF blockers; infliximab and Etanercept. Nihon Rinsho, 2007, 65(7), 1282-1286.
61. Elliott, M. J.; Maini, R. N.; Feldmann, M.; Long-Fox, A.; Charles, P.; Katsikis, P.; Brennan, F. M.; Walker, J.; Bijl, H.; Ghrayeb, J.; Woody, J. N.; Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum., 1993, 36,1681-1690.
62. Taylor, P.; Patel, S.; Paleolog, E.; McCloskey, R.; Feldmann, M.; Maini, R. N. Reduced synovial vascularity following TNFα blockade in RA. Arthritis Rheum., 1998, 41(1), S295.
63. Paleolog, E. M.; Young, S.; Stark, A. C.; McCloskey, R. V.; Feldmann, M.; Maini, R. N; Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1in rheumatoid arthritis. Arthritis Rheum., 1998, 41, 1258-1265.
64. Nahar, I. K.; Shojania, K.; Marra, C. A.; Alamgir, A. H.; Anis, A. H. Infliximab treatment of rheumatoid arthritis and Crohn’s disease. Ann. Pharmacother., 2003, 37(9), 1256-1265.
65. Oosterhout, M. V.; Levarht, E. N.; Sont, J. K.; Huizinga T. W.; Toes, R. E.; Van, J. M. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNFα and IL18 but not CXCL12. Ann. Rheum. Dis., 2005, 64, 537-543.
66. Sarah, L.; James, P.; Christine, H.; Patrick, K. Intra-articular infliximab in DMARD-resistant knee monoarthritis: clinical and ultrasound responses. Int. J. Clin. Rheumatol., 2011, 6(2), 231-239.
67. Boulos, H.; Vivian, B. Etanercept in the treatment of rheumatoid arthritis. Ther. Clin. Risk Manag., 2007, 3(1), 99-105.
68. Verschueren, P. C.; Markusse, H.; Smeets, T.J. Reduced cellularity and expression of adhesion molecules and cytokines after treatment with soluble human recombinant TNF receptor (p75) in RA patients. Arthritis Rheum., 1999, 42(l), S197, 762.
69. Korth-Bradley, J. M.; Rubin, A. S.; Hanna, R. K.; Simcoe, D. K.; Lebsack, M. E. The pharmacokinetics of etanercept in healthy volunteers. Ann. Pharmacother., 2000, 34(2), 161-164.
70. Genentech Actemra®. Prescribing Information. http://www.gene.com/gene/products/information/actemra/pdf/pi.pdf. (accessed on Oct 9, 2013).
71. Patel, A. M.; Moreland, L.W. Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy. Drug Des. Devel. Ther., 2010, 4, 263-278.
72. Filip, K. Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective. Curr. Rheumatol. Rev., 2011, 7(1), 77-87.
73. Doran, M. F.; Crowson, C. S.; Pond, G. R. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum., 2002, 46, 2287-2293.
74. Carla, R.; Figgie, M. P.; Nestor, B. J.; Goodman, S. M. Perioperative management of medications used in the treatment of rheumatoid arthritis. HSS J., 2006, 2(2), 141-147.
75. Simard, J. F.; Neovius, M.; Hagelberg, S. Juvenile idiopathic arthritis and risk of cancer: A nationwide cohort study. Arthritis Rheum., 2010, 62(12), 3776-3782.
76. Ryu, Y. S.; Park, S. H.; Kim, J. M.; Kim, E. J.; Lee, J.; Kwok, S. K.; Ju, J.H.; Kim, H. Y. A case of leukoencephalopathy associated with adalimumab-treated rheumatoid arthritis and a review of literature. Rheumatol. Int., 2012, 32(11), 3481-3485.
77. Sarzi-Puttini, P.; Atzeni, F.; Shoenfeld, Y.; Ferraccioli G.; TNF-α, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun. Rev., 2005, 4(3), 153-161.
78. Sokolove, J.; Strand, V.; Greenberg, J. D.; Curtis, J. R.; Kavanaugh, A.; Kremer, J. M.; Anofrei, A.; Reed, G.; Calabrese, L.; Hooper, M.; Baumgartner, S.; Furst, D.E. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2010, 69(9), 1612-1617.
79. De Gannes, G. C.; Ghoreishi, M.; Pope, J.; Russell, A.; Bell, D.; Adams, S.; Shojania, K.; Martinka, M.; Dutz, J. P. Psoriasis and pustular dermatitis triggered by TNF-{α} inhibitors in patients with rheumatologic conditions. Arch. Dermatol., 2007, 143(2), 223-231.
80. Gout, T.; Ostor, A.J.; Nisar, M. K. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin. Rheumatol., 2011, 30(11), 1471-1474.
81. Lyudmila, S. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. Br. J. Clin. Pharmacol., 2008, 66(2), 173-178.
82. National Rheumatoid Arthritis Society. Combination therapy for rheumatoid arthritis. http://www.nras.org.uk/about_rheumatoid_arthritis/newly_diagnosed/which_drugs_are_used/combination_therapy_for_rheumatoid_arthritis. (accessed on Nov 25, 2013).
83. http://www.medscape.org/viewarticle/560135 (accessed on Dec 29, 2013).
84. Alex, K.; Heather, M.; Remy, C.; John, W.; Gillian, S. Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis. BMC Pediatrics, 2012, 12(29), 1471-2431.
85. Gilberto, P.; Silvio, L.; Massimo. C.; Filippo, P.; Paolo, G.; Federica, U.; Lorenzo, G.; Piero, B.; Fernando, R.; Maurizio, C. Infliximab in the treatment of Crohn’s disease. Ther. Clin. Risk Manag., 2007, 3(2), 301-308.
86. Kim, S.; Yelin, E.; Tonner, C.; Solomon, D. Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009. Arthritis Care Res. (Hoboken), 2013, 65(9), 1529-1533.
87. Dimple, C.; Monica, G.; Saranjit, S.; Sanjiv, D.; Rajiv, K. Use of liposomal drugs in the treatment of rheumatoid arthritis. Curr. Rheumatol. Rev., 2008, 4, 63-70.
88. Patricia, G. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis? J. Family Pract., 2007, 56(11), 933-937.